These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 226834)

  • 1. Effects of estrogen therapy on apolipoprotein E in type II hyperlipoproteinemia.
    Falko JM; Schonfeld G; Witztum JL; Kolar J; Weidman SW
    Metabolism; 1979 Nov; 28(11):1171-7. PubMed ID: 226834
    [No Abstract]   [Full Text] [Related]  

  • 2. A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia.
    Stuyt PM; Demacker PN; van't Laar A
    Horm Metab Res; 1986 Sep; 18(9):607-10. PubMed ID: 3465673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary report: treatment of type 3 hyperlipoproteinemia with mevinolin.
    East CA; Grundy SM; Bilheimer DW
    Metabolism; 1986 Feb; 35(2):97-8. PubMed ID: 3633017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of diet on apoprotein E levels and on the apoprotein E subspecies in human plasma lipoproteins.
    Falko JM; Schonfeld G; Witztum JL; Kolar JB; Weidman SW; Steelman R
    J Clin Endocrinol Metab; 1980 Mar; 50(3):521-8. PubMed ID: 7358833
    [No Abstract]   [Full Text] [Related]  

  • 5. Type III hyperlipoproteinemia associated with apolipoprotein E deficiency.
    Ghiselli G; Schaefer EJ; Gascon P; Breser HB
    Science; 1981 Dec; 214(4526):1239-41. PubMed ID: 6795720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type III hyperlipoproteinemia: rise in high-density lipoprotein levels in response to therapy.
    Falko JM; Witztum JL; Schonfeld G; Weidman SW; Kolar JB
    Am J Med; 1979 Feb; 66(2):303-10. PubMed ID: 218451
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia.
    Ehnholm C; Mahley RW; Chappell DA; Weisgraber KH; Ludwig E; Witztum JL
    Proc Natl Acad Sci U S A; 1984 Sep; 81(17):5566-70. PubMed ID: 6591204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Apolipoproteins - an important diagnostic indicator in the evaluation of coronary disease risk].
    Naruszewicz M; Nowicka G
    Pol Arch Med Wewn; 1980 Aug; 64(2):161-6. PubMed ID: 7433154
    [No Abstract]   [Full Text] [Related]  

  • 9. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia.
    Schonfeld G; George PK; Miller J; Reilly P; Witztum J
    Metabolism; 1979 Oct; 28(10):1001-10. PubMed ID: 226830
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipids during postmenopausal treatment with estradiol valerianate and ethinyl estradiol-preliminary communication.
    Wallentin L; Larsson-Cohn U
    Acta Obstet Gynecol Scand Suppl; 1977; 65():65-7. PubMed ID: 199038
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogen.
    Kushwaha RS; Hazzard WR; Gagne C; Chait A; Albers JJ
    Ann Intern Med; 1977 Nov; 87(5):517-25. PubMed ID: 200161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in very low and low density lipoproteins with dietary fat modification.
    Weisweiler P; Drosner M; Janetschek P; Schwandt P
    Atherosclerosis; 1983 Dec; 49(3):325-32. PubMed ID: 6661270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the serum total cholesterol an anachronism?
    Kannel WB; Castelli WP
    Lancet; 1979 Nov; 2(8149):950-1. PubMed ID: 91037
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia.
    Packard CJ; Stewart JM; Third JL; Morgan HG; Lawrie TD; Shepherd J
    Biochim Biophys Acta; 1980 Apr; 618(1):53-62. PubMed ID: 6990991
    [No Abstract]   [Full Text] [Related]  

  • 18. Apolipoprotein E (role in lipoprotein metabolism and pathophysiology of hyperlipoproteinemia type III).
    Utermann G
    Ric Clin Lab; 1982; 12(1):23-30. PubMed ID: 6283616
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.
    Kibata M; Ishida M; Asano K; Uehara H; Saito K; Fuchimoto T; Ugaki K; Murakami H; Matoba K; Kotakemori Y; Shirai K; Yoshioka H; Nanba M; Yasuda M; Ishizaki M; Kitagawa N; Ikejiri K; Inohara R; Lee BJ; Saino S; Sakado J; Matuzaka H; Numata K; Mandai M; Miyake K; Nakamura K
    Atherosclerosis; 1980 Nov; 37(3):333-42. PubMed ID: 7458980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arteriosclerosis. III. Laboratory diagnosis of dyslipoproteinemia].
    Nowicka G; Kłosiewicz-Latoszek L
    Wiad Lek; 1985 Aug; 38(16):1179-84. PubMed ID: 4082589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.